ELIANSH(SH:600836)2021-10-26 16:00Financial Performance - The company's operating revenue for Q3 2021 was ¥155,028,655.33, a decrease of 48.11% compared to the same period last year[2]. - The net profit attributable to shareholders was -¥17,915,203.42, representing a decline of 519.65% year-on-year[2]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥25,686,659.09, with a year-on-year change of -303.87%[2]. - Total operating revenue for the first three quarters of 2021 was CNY 588,548,386.42, a significant decrease from CNY 1,901,605,047.27 in the same period of 2020, representing a decline of approximately 69.0%[24]. - The net profit for Q3 2021 was CNY 129,232,190.48, a decrease of 49.6% compared to CNY 255,979,773.60 in Q3 2020[25]. - The operating profit for Q3 2021 was CNY 161,523,924.00, down from CNY 278,897,583.75 in the same period last year, reflecting a decline of 42.3%[25]. - Basic and diluted earnings per share for Q3 2021 were both CNY 0.193, down from CNY 0.342 in Q3 2020, reflecting a decrease of 43.7%[27]. - The total comprehensive income for Q3 2021 was CNY 129,232,190.48, a decrease of 49.6% from CNY 255,979,773.60 in Q3 2020[26]. Cash Flow and Assets - The net cash flow from operating activities for the year-to-date was ¥45,126,963.65, an increase compared to the previous year[2]. - The company's cash and cash equivalents increased to CNY 748,238,443.80 as of September 30, 2021, up from CNY 250,324,357.17 at the end of 2020, marking a rise of about 198.5%[20]. - The cash flow from operating activities for the first three quarters of 2021 was CNY 45,126,963.65, compared to CNY 532,049.35 in the same period last year, indicating a substantial improvement[28]. - The company reported a net cash inflow from investing activities of CNY 232,452,975.99 for the first three quarters of 2021, up from CNY 127,418,571.37 in the previous year[29]. - The company achieved a net cash inflow from financing activities of CNY 165,855,362.28 in Q3 2021, compared to a net outflow of CNY 184,972,377.41 in Q3 2020[29]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 36,757[9]. - The largest shareholder, Hangzhou Zhefa Yilian Business Management Partnership (Limited Partnership), holds 180,468,652 shares, accounting for 27.23% of total shares[9]. - The first ten shareholders do not have any associated relationships with each other, and the company is unaware of any other shareholders' relationships[10]. Equity and Stock Plans - The company plans to issue 100 million A-shares at a price of 5.11 RMB per share, subject to approval by the China Securities Regulatory Commission[14]. - The company has approved a stock incentive plan involving 10 million restricted stocks, with 8.3 million stocks to be granted initially[15]. - The company will hold a shareholder meeting on October 28, 2021, to review the stock incentive plan and related matters[16]. Liabilities and Assets - Total assets at the end of the reporting period were ¥2,040,079,633.82, an increase of 2.08% from the end of the previous year[3]. - The company's total liabilities decreased to CNY 859,386,626.96 as of September 30, 2021, down from CNY 933,957,646.65 at the end of 2020, indicating a reduction of about 7.9%[22]. - The company's short-term borrowings increased to CNY 447,929,163.89 as of September 30, 2021, compared to CNY 256,016,919.85 at the end of 2020, representing an increase of approximately 75.0%[22]. - The company's non-current assets totaled CNY 941,447,476.42 as of September 30, 2021, compared to CNY 907,334,187.28 at the end of 2020, reflecting an increase of approximately 3.8%[21]. Operational Changes - The significant decrease in operating revenue was primarily due to reduced income from real estate projects compared to the previous year[6]. - The company reported a decrease in net profit due to lower investment income from equity transfers and real estate projects[6]. - The company experienced a net cash flow increase due to reduced payments for accounts payable compared to the previous year[6]. - The company has completed the acquisition of a land use right for a biopharmaceutical industrial base project covering 106,625 square meters (approximately 160 acres) in JianDe City[18]. - The company is actively conducting nationwide research and planning for pharmaceutical industry and product targets, with ongoing preliminary preparations for the project[18]. - The company completed the internal transfer of 100% equity of subsidiaries Shanghai Xundian Yutian Printing Co., Ltd. and Shanghai Xundian Yongfa Packaging Printing Co., Ltd. for a transfer price of 0 RMB each[11]. - The company transferred 100% equity of Zhejiang Jielong Yutian Packaging Co., Ltd. to Beijing Jielong International Trade Co., Ltd. for a price of 5 million RMB, with the payment fully received[12]. Legal Matters - The company has received a total of 36 civil lawsuits related to securities false statements, with 31 cases allowing the plaintiffs to withdraw their lawsuits[17].